AgomAb Therapeutics NV AGMB
—
10.51
(0.07)
(0.66%)
as of 25 Sep
- Market cap
- $521.1M
- P/E
- —
Follow AGMB
| Dec '25 | Dec '24 | |
|---|---|---|
Current Ratio |
6.52 | 19.05 |
Net Debt/EBITDA |
1.96 | 3.57 |
Debt/Assets |
0.65% | 0.62% |
Debt/Equity |
0.01 | 0.01 |
Asset Turnover |
0.00 | — |
Operating CF/Net income |
0.67 | 0.81 |
Capex/Depreciation |
(0.02) | (2.17) |
Interest Coverage |
0.00 | 0.00 |
| (49.87%) | 0.00% | |
| (44.15%) | 0.00% | |
ROIC |
(240.67%) | (167.73%) |
Return on Tangible Assets |
(75.13%) | (34.99%) |
Research and Development Expense of Revenue |
0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.19 | 0.14 |
Share Based Compensation of Revenue |
0.00% | 0.00% |
Free Cash Flow per Share |
(108.19) | (2.06) |
Cash per Share |
243.62 | 7.42 |
Shareholders Equity per Share |
273.71 | 8.14 |
Interest Debt per Share |
0.00 | 0.00 |
Book value per Share |
273.71 | 8.14 |
Free Cash Flow |
(58.54) | (51.40) |
Working Capital |
116.14 | 178.24 |
Capital Expenditures |
0.00 | (0.73) |
Net Current Asset Value |
111.37 | 168.34 |
| Other line items | ||
Quick Ratio |
6.27 | 18.79 |
Depreciation/Fixed assets |
0.44 | 0.50 |
Cash ROIC |
(21.03%) | (13.15%) |
Accounts Payable Turnover |
0.00 | — |
Average Days of Payables |
0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 |
Operating CF per Share |
(108.19) | (2.03) |
Capex per Share |
(0.01) | (0.03) |
Average Payables |
10.16 | — |
Average Assets |
198.60 | — |
Average Common Equity |
175.81 | — |
Capex to Sales |
0.00 | 0.00 |
Net Profit Margin |
0.00% | 0.00% |
Columns are period end dates